CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by EMC Capital Management

EMC Capital Management reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 64.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,330 shares of the company’s stock after selling 5,970 shares during the period. EMC Capital Management’s holdings in CRISPR Therapeutics were worth $156,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in CRSP. Riggs Asset Managment Co. Inc. lifted its position in CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the period. SFE Investment Counsel lifted its holdings in shares of CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after buying an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after buying an additional 211 shares during the last quarter. Orion Capital Management LLC grew its holdings in CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after acquiring an additional 220 shares during the period. Finally, National Bank of Canada FI grew its holdings in CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $50.76 on Friday. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The stock has a market cap of $4.32 billion, a P/E ratio of -15.72 and a beta of 1.68. The stock’s 50 day simple moving average is $47.11 and its 200-day simple moving average is $52.44.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. During the same period in the prior year, the firm posted ($0.98) EPS. The firm’s quarterly revenue was down 99.3% compared to the same quarter last year. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.57 EPS for the current fiscal year.

Analysts Set New Price Targets

CRSP has been the topic of several recent research reports. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Truist Financial lowered their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Barclays lowered their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus cut their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $75.19.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.